(95% CI: 12.49-14.65) for the platinum-sensitive recurrence group, while the median overall survival (OS) was not reached in either group.Conclusions:This pioneering multicentric study sheds light on the landscape of primary platinum-resistant ovarian cancer in India, revealing critical gaps in ...
www.nature.com/scientificreports OPEN AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin Susann Badmann1, Doris Mayr2, Elisa Schmoeckel2, Anna Hester1, Christina Buschmann1, Susanne Beyer1, Thomas Kolben1, Fabian Kraus1, Anca ...
3g). Elevated C/EBPβ expression after platinum-based chemotherapy was also observed in paired ovarian cancer specimens (Fig. 3h), a finding which was consistent with higher cell viability in C/EBPβ-expressing cells. Thus, under the pressure of cisplatin, a tumor may become more resistant ...
3g). Elevated C/EBPβ expression after platinum-based chemotherapy was also observed in paired ovarian cancer specimens (Fig. 3h), a finding which was consistent with higher cell viability in C/EBPβ-expressing cells. Thus, under the pressure of cisplatin, a tumor may become more resistant ...
Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), treatment options are limited, and their survival prospe...
Journal of Ovarian Research (2015) 8:13 Page 12 of 14 Conclusions The altered metabolism of cancer cells has been well established. Our data shows that platinum sensitive and resistant ovarian cancer cells can be distinguished based on their metabolite profiles. This suggests that chemore- si...
Platinum is a key component of ovarian cancer systemic therapy. However, most patients will eventually face a recurrence, leading to chemotherapy resistance, especially against platinum. For individuals with platinum-resistant ovarian cancer (PROC), trea
Collectively, these properties provide the rationale to investigate the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. 2. Methods 2.1. Study design This was a Phase I, multicenter, open-label, dose-escalation study of DMUC4064A. The study employed a ...
CXCR2 overexpression has been demonstrated to promote ovarian cancer progression [32, 33]. However, there is a lack of research about the role of CXCL2 and the regulation mechanism in platinum-resistant EOC. Herein, this study systematically explored the molecule biological function and the ...
Neoadjuvant chemotherapy followed by interval debulking surgery is currently a common treatment option for advanced epithelial ovarian cancer (EOC). The Standardized CA-125 ELIMination rate constant K (Std KELIM) and the Platinum Resistant Recurrence (PtRR) Score have been proposed as markers of tumor...